Abcam, ab209667, Anti-MAGEC2 antibody [EPR19064]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal MAGEC2 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Recombinant full length protein samples. Cited in 5 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19064,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, IP, Flow Cyt (Intra), ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAGEC2 also known as melanoma-associated antigen C2 or CT10 is a protein with a molecular mass of approximately 60 kDa. Researchers have found it expressed mostly in human cancerous tissues particularly in melanoma but not in normal tissues except for the testis. This restricted expression pattern has made MAGEC2 an interesting target for cancer immunotherapy and diagnosis. Its presence varies between different cancer types influencing its potential as a biomarker or therapeutic target.
Biological function summary
MAGEC2 interacts with cellular mechanisms related to cell growth and proliferation. The protein plays a role in processes linked to cancer progression by modulating transcriptional activities through its interaction with other proteins. MAGEC2 is not known to be part of a specific protein complex but its function associates with the ubiquitination process and modulation of p53 a well-known tumor suppressor protein. These interactions suggest critical roles in tumor maintenance and survival.
Pathways
MAGEC2's influence extends to oncogenic pathways involving cell cycle regulation and DNA damage response. It plays a part in the p53 signaling pathway where it impacts p53 stability and activity emphasizing its importance in cancer biology. Additionally connections with the E2F transcription factor highlight its potential role in regulating a series of genes important for cell cycle progression suggesting a strong interplay with cellular division processes.
The aberrant expression of MAGEC2 relates most closely to melanomas and carcinomas which demonstrate increased levels of this protein. The association with these cancers emphasizes its potential as a target for cancer immunotherapy. In melanomas MAGEC2 often implicates with the dysregulation of the p53 protein contributing to unchecked cell division and tumor growth. Other cancer types may show similar associations highlighting the universality of MAGEC2's role in tumorigenic processes.